Frankfurt - Delayed Quote EUR

Teva Pharmaceutical Industries Limited (TEV.F)

Compare
16.00 -0.05 (-0.31%)
At close: June 14 at 4:10 PM GMT+2
Loading Chart for TEV.F
DELL
  • Previous Close 16.05
  • Open 16.20
  • Bid --
  • Ask --
  • Day's Range 16.00 - 16.25
  • 52 Week Range 6.68 - 16.25
  • Volume 1,916
  • Avg. Volume 6,396
  • Market Cap (intraday) 18.122B
  • Beta (5Y Monthly) 0.91
  • PE Ratio (TTM) --
  • EPS (TTM) -0.39
  • Earnings Date Jul 31, 2024 - Aug 5, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Nov 27, 2017
  • 1y Target Est 11.47

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

www.tevapharm.com

35,001

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TEV.F

Performance Overview: TEV.F

Trailing total returns as of 6/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TEV.F
74.67%
TA-125
3.88%

1-Year Return

TEV.F
129.89%
TA-125
5.85%

3-Year Return

TEV.F
78.97%
TA-125
9.77%

5-Year Return

TEV.F
117.39%
TA-125
34.72%

Compare To: TEV.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TEV.F

Valuation Measures

Annual
As of 6/14/2024
  • Market Cap

    18.07B

  • Enterprise Value

    33.85B

  • Trailing P/E

    --

  • Forward P/E

    9.07

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.20

  • Price/Book (mrq)

    2.67

  • Enterprise Value/Revenue

    2.27

  • Enterprise Value/EBITDA

    27.52

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -2.99%

  • Return on Assets (ttm)

    4.84%

  • Return on Equity (ttm)

    -9.67%

  • Revenue (ttm)

    16B

  • Net Income Avi to Common (ttm)

    -478M

  • Diluted EPS (ttm)

    -0.39

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.99B

  • Total Debt/Equity (mrq)

    264.33%

  • Levered Free Cash Flow (ttm)

    3.57B

Research Analysis: TEV.F

Company Insights: TEV.F

Research Reports: TEV.F

People Also Watch